vorinostat has been researched along with Pleural Effusion, Malignant in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Pleural Effusion, Malignant: Presence of fluid in the PLEURAL CAVITY as a complication of malignant disease. Malignant pleural effusions often contain actual malignant cells.
Excerpt | Relevance | Reference |
---|---|---|
"Treatment with vorinostat, a histone deacetylase inhibitor (HDACi) resulted in an objective response, yet she died in less than one year from initial diagnosis." | 1.42 | Histone deacetylase inhibitor for NUT midline carcinoma. ( Bell, D; Christensen, AM; Maher, OM; Tarek, N; Yedururi, S, 2015) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Maher, OM | 1 |
Christensen, AM | 1 |
Yedururi, S | 1 |
Bell, D | 1 |
Tarek, N | 1 |
1 other study available for vorinostat and Pleural Effusion, Malignant
Article | Year |
---|---|
Histone deacetylase inhibitor for NUT midline carcinoma.
Topics: Adolescent; Carcinoma; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mandibular | 2015 |